Industry News

EndoChoice, which markets a variety of gastrointestinal endoscopy products, headed by the Full Spectrum Endoscope, a unique Israeli-developed colonscope, today announced that it would be acquired by Boston Scientific for $210 million. EndoChoice is listed on Nasdaq at a $109 million market cap, meaning that the acquisition is at a premium of almost 100%. EndoChoice held its IPO in 2015, raising $96 million at a company value of $366 million, after money, and reached a peak..."/>
Boston Scientific buys EndoChoice for $210m [Globes, Tel Aviv, Israel]
Xencor has expanded its San Diego operations, the Monrovia-based biotech said last week. The San Diego office now has 17 employees, said president and CEO Bassil Dahiyat. It had about four when it was opened about two years ago, They're handling clinical development and regulatory affairs."/>
Xencor grows in San Diego [The San Diego Union-Tribune]
Cantel Medical Corp has acquired endoscope reprocessing business assets from its Canadian medical products distributor, Vantage Endoscopy, Inc, the company said. Terms of the deal were not disclosed. The endoscope reprocessing business consists of Cantel's Medivators-branded automated endoscope reprocessors, chemistries, consumables and a full sales and service organization."/>
Cantel Medical Acquires Endoscopy Assets from Vantage Endoscopy
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, President and Chief Executive Officer, David Riggs, Chief Financial Officer, and other members of Eagle's senior management team will host an Investor Day in New York City on November 11, 2016.. The event will focus on the Company's growth initiatives, R&D pipeline and financial outlook. It will provide additional insight on Ryanodex ® for Exertional Heat Stroke and Methamphetamine and..."/>
Eagle Pharmaceuticals Announces “Save the Date” for 2016 Investor Day
Array BioPharma today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30- day option to purchase up to an additional $15 million of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma."/>
Array BioPharma Announces Proposed Public Offering of Common Stock
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that Dawn Svoronos has been appointed to its Board of Directors. Svoronos is a pharmaceutical industry executive whose experience includes a 23- year career at Merck& Co. with a focus on commercial operations and marketing, as well as board positions at Medivation Inc. and Theratechnologies Inc.. Simon Pimstone, Xenon’ s President and Chief..."/>
Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
Dextera Surgical Inc., manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced two presentations featuring the company’ s MicroCutter 5/ 80 surgical stapler at the Annual Meeting of the German Society for Thoracic Surgery in Freiburg, Germany.. The use of the MicroCutter 5/ 80 to enable new and innovative procedures was discussed during..."/>
Dextera Surgical’s MicroCutter Technology Highlighted at Annual Meeting of the German Society for Thoracic Surgery
Gilead Sciences, Inc. today announced it has entered into a partnership with the World Health Organization to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis. As part of this collaboration, Gilead will donate 380,000 vials of AmBisome ® to meet the needs..."/>
Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced that it intends to commence an underwritten public offering of its ordinary shares. A portion of the shares will be sold by certain selling shareholders. Foamix also intends to grant the underwriters a 30-..."/>
Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary Shares
Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced data from the Company’ s GALE-301 Phase 1/ 2 a clinical trial was presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY. The focus of the presentation was on the association between clinical outcomes and..."/>
Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
ResMed Inc. today announced it will report its first quarter of fiscal year 2017 results on Tuesday, October 25, 2016 after the New York Stock Exchange market closes. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and future outlook. The earnings webcast is scheduled to begin at 1:30 p.m. US Pacific Time and the live webcast of the call can be..."/>
ResMed to Announce First Quarter Fiscal Year 2017 Results
Titan Medical Inc., a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery, today provided an update of corporate activities and operational progress. On September 20 2016, Titan completed a public offering of units which raised approximately US $7.2 million from US and Canadian investors. As a result of the transaction, management currently anticipates closing the..."/>
Titan Medical Provides Corporate Update
Galapagos NV reports the successful completion of discussions with the regulatory authorities in the US and Europe to initiate the DIVERSITY Phase 3 study in Crohn's disease and the SELECTION Phase 2 b/3 study in ulcerative colitis with filgotinib. Both studies will..."/>
Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease
Versartis, Inc., an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone for growth hormone deficiency, today announced that it has commenced an underwritten public offering of shares of its common stock. The company expects to grant the underwriters a 30- day option to purchase up to an additional 15 percent of the number of shares of common stock sold in..."/>
Versartis Announces Proposed Offering of Common Stock
Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the third quarter of 2016 on November 3, 2016 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m.. The link to the live call will be available on the Investor Relations section of the Company's website at..."/>
Insulet Corporation to Announce Third Quarter 2016 Financial Results on November 3, 2016
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced the Company has appointed Habib Dable as President and Chief Executive Officer to succeed current President and CEO..."/>
Acceleron Announces Retirement of John Knopf as President and CEO; Habib Dable Named as Successor
Galapagos NV reports the successful completion of discussions with the regulatory authorities in the US and Europe to initiate the DIVERSITY Phase 3 study in Crohn's disease and the SELECTION Phase 2 b/3 study in ulcerative colitis with filgotinib. Both studies will..."/>
Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease
Quest Diagnostics, the world's leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Friday, November 11, 2016 at The Intercontinental New York Barclay Hotel, 111 East 48th St, New York, NY. During the event, President and Chief Executive Officer Steve Rusckowski, Chief Financial Officer Mark Guinan, and other senior executives will share..."/>
Quest Diagnostics To Host Investor Day On November 11, 2016
Spectrum Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California. The complaint is brought on behalf of all purchasers of Spectrum securities between December 16, 2015 and September 16, 2016, for alleged violations of the Securities Exchange Act of 1934 by Spectrum's officers and directors."/>
Robbins Arroyo LLP: Spectrum Pharmaceuticals, Inc. (SPPI) Misled Shareholders According to a Recently Filed Class Action
Allergan, a $4 billion-a-year maker of skin and eye care products. The company's treatment uses a virus to deliver a photoreceptor gene from the algae into a human..."/>
WSU research leads to algae treatment for blindness [Detroit Free Press]
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510 clearance from the United States Food and Drug Administration to market its Solana ® Influenza A+ B assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the diagnosis of Influenza A and B..."/>
Quidel Receives FDA Clearance for Its Solana(R) Influenza A+B Assay in Time for the Upcoming 2016-2017 Flu Season
Abattis Bioceuticals Corp. is pleased to announce the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. Xie graduated from Zhejiang University in 1987 and Queen's University in 1993."/>
Update: New Science Advisor and Comptroller Appointment to Abattis

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology657 Articles
Consumer Discretionary579 Articles
Financials366 Articles
Industrials364 Articles
Health Care342 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.